



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Draghia-Akli, et. al.

Serial No.: 10/619,939

Filed: July 15, 2003

Group: Unknown

For: CODON OPTIMIZED SYNTHETIC PLASMIDS

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

CERTIFICATE OF MAILING UNDER 37 CFR 1.8: I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on November 11, 2003.

M. Alford
Signature

M. ALFORD

Typed or Printed name of person signing Certificate

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN
THREE MONTHS OF FILING OR BEFORE MAILING OF FIRST OFFICE
ACTION

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, whichever event occurs last 37 C.F.R. § 1.97(b).


Respectfully submitted,
JACKSON WALKER L.L.P.

T. Ling Chwang

T. Ling Chwang
Registration No. 33,590

Dated: November 11, 2003

JACKSON WALKER L.L.P.
2435 North Central Expressway, Suite 600
Richardson, Texas 75080
Tel: (972) 744-2919
Fax: (972) 744-2909



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 6 Sheets

Complete if Known

Application Number	10/619,939
Filing Date	7/15/2003
First Named Inventor	Draghia-Akli, Ruxandra
Group Art Unit	
Examiner Name	
Attorney Docket Number	108328.00146 (AVSI-0023)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/	6	AIHARA, H. and Miyazaki, J. (1998). Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. 16, 867-870.	
/	7	BAIRD, A., Wehrenberg, W. B., and Ling, N. (1986). Relative potencies of human, rat, bovine/caprine, porcine and ovine hypothalamic growth hormone-releasing factors to release growth hormone by the rat anterior pituitary in vitro. Neuroendocrinology 42, 273-276.	
/	8	BERCU, B. B., Walker, R. F., (1997). Growth Hormone Secretagogues In Children With Altered Growth. Acta Paediatrica 86, 102-106.	
/	9	BLETHEN, S. L. (1995). Complications of growth hormone therapy in children. Curr. Opin. Pediatr. 7, 466-471.	
/	10	BLETHEN, S. L. and Rundle, A.C. (1996). Slipped capital femoral epiphysis in children treated with growth hormone. A summary of the National Cooperative Growth Study experience. Horm. Res. 46, 113-116.	
/	11	BOHLEN, P., Esch, F., Brazeau, P., Ling, N., and Guillemin, R. (1983). Isolation and characterization of the porcine hypothalamic growth hormone releasing factor. Biochem. Biophys. Res. Commun. 116, 726-734.	
/	12	BOHLEN, P., Wehrenberg, W. B., Esch, F., Ling, N., Brazeau, P., and Guillemin, R. (1984). Rat hypothalamic growth hormone-releasing factor: isolation, sequence analysis and total synthesis. Biochemical & Biophysical Research Communications 125, 1005-1012.	
/	13	BRAZEAU, P., Bohlen, P., Esch, F., Ling, N., Wehrenberg, W. B., and Guillemin, R. (1984). Growth hormone-releasing factor from ovine and caprine hypothalamus: isolation, sequence analysis and total synthesis. Biochemical & Biophysical Research Communications 125, 606-614.	
/	14	BURGERT, T. S., Vuguin, P. M., DiMartino-Nardi, J., Attie, K. M., and Saenger, P. (2002). Assessing insulin resistance: application of a fasting glucose to insulin ratio in growth hormone-treated children. Horm. Res. 57, 37-42.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



NOV 1 4 2003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 6 Sheets

Complete if Known

Application Number	10/619,939
Filing Date	7/15/2003
First Named Inventor	Draghia-Akli, Ruxandra
Group Art Unit	
Examiner Name	
Attorney Docket Number	108328.00146 (AVSI-0023)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/	15	CARREL, A. L. and Allen, D. B. (2000). Effects of growth hormone on body composition and bone metabolism. <i>Endocrine</i> . 12, 163-172.	
/	16	CORPAS, E., Harman, S. M., and Blackman, M. R. (1993a). Human growth hormone and human aging. [Review]. <i>Endocrine Reviews</i> 14, 20-39.	
/	17	CORPAS, E., Harman, S. M., Pineyro, M. A., Roberson, R., and Blackman, M. R. (1993b). Continuous subcutaneous infusions of growth hormone (GH) releasing hormone 1-44 for 14 days increase GH and insulin-like growth factor-I levels in old men. <i>Journal of Clinical Endocrinology & Metabolism</i> 76, 134-138.	
/	18	CUTTLER, L. (1996). The regulation of growth hormone secretion. <i>Endocrinol. Metab Clin. North Am.</i> 25, 541-571.	
/	19	DANKO, I. and Wolff, J. A. (1994). Direct gene transfer into muscle. [Review]. <i>Vaccine</i> 12, 1499-1502.	
/	20	DARQUET, A. M., Cameron, B., Wils, P., Scherman, D., and Crouzet, J. (1997). A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. <i>Gene Ther.</i> 4, 1341-1349.	
/	21	DARQUET, A. M., Rangara, R., Kreiss, P., Schwartz, B., Naimi, S., Delaere, P., Crouzet, J., and Scherman, D. (1999). Minicircle: an improved DNA molecule for in vitro and in vivo gene transfer. <i>Gene Ther.</i> 6, 209-218.	
/	22	DRAGHIA-AKLI, R., Fiorotto, M. L., Hill, L. A., Malone, P. B., Deaver, D. R., and Schwartz, R. J. (1999). Myogenic expression of an injectable protease-resistant growth hormone-releasing hormone augments long-term growth in pigs. <i>Nat. Biotechnol.</i> 17, 1179-1183.	
/	23	DRAGHIA-AKLI, R., Li, X. G., Schwartz, R. J. (1997). Enhanced Growth By Ectopic Expression Of Growth Hormone Releasing Hormone Using An Injectable Myogenic Vector. <i>nature biotechnology</i> 15, 1285-1289.	
/	24	DRAGHIA-AKLI, R., Malone, P. B., Hill, L. A., Ellis, K. M., Schwartz, R. J., and Nordstrom, J. L. (2002). Enhanced animal growth via ligand-regulated GHRH myogenic-injectable vectors. <i>FASEB J.</i> 16, 426-428.	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 6 Sheets

Complete if Known

Application Number	10/619,939
Filing Date	7/15/2003
First Named Inventor	Draghia-Akli, Ruxandra
Group Art Unit	
Examiner Name	
Attorney Docket Number	108328.00146 (AVSI-0023)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/	25	DUCK, S. C., et al., (1992). Subcutaneous growth hormone-releasing hormone therapy in growth hormone-deficient children: first year of therapy. Journal of Clinical Endocrinology & Metabolism 75, 1115-1120.	
/	26	ESCH, F., Bohlen, P., Ling, N., Brazeau, P., and Guillemin, R. (1983). Isolation and characterization of the bovine hypothalamic growth hormone releasing factor. Biochemical & Biophysical Research Communications 117, 772-779.	
/	27	EVANS, W. S., Vance, M. L. et al., (1985). Effects of intravenous, subcutaneous, and intranasal administration of growth hormone (GH)-releasing hormone-40 on serum GH concentrations in normal men. Journal of Clinical Endocrinology & Metabolism 61, 846-850.	
/	28	FAGLIA, G., Arosio, M., and Bazzoni, N. (1992). Ectopic acromegaly. [Review]. Endocrinology & Metabolism Clinics of North America 21, 575-595.	
/	29	FROHMAN, L. A., Downs, T. R., and Chomczynski, P. (1992). Regulation of growth hormone secretion. [Review]. Frontiers in Neuroendocrinology 13, 344-405.	
/	30	FROHMAN, L. A., Downs, T. R., Heimer, E. P., and Felix, A. M. (1989a). Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J. Clin. Invest. 83, 1533-1540.	
/	31	FROHMAN, L. A., Downs, T. R., Williams, T. C., Heimer, E.P., Pan, Y.C., and Felix, A.M. (1986). Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J. Clin. Invest. 78, 906-913.	
/	32	GEFFNER, M. (1997). Effects of growth hormone and insulin-like growth factor I. Acta Paediatr. Suppl 423, 76-79.	
/	33	HART, D. W., Herndon, D. N., Klein, G., Lee, S. B., Celis, M., Mohan, S., Chinkes, D. L., and Wolf, S. E. (2001). Attenuation of posttraumatic muscle catabolism and osteopenia by long-term growth hormone therapy. Ann. Surg. 233, 827-834.	


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 6 Sheets

Complete if Known

Application Number	10/619,939
Filing Date	7/15/2003
First Named Inventor	Draghia-Akli, Ruxandra
Group Art Unit	
Examiner Name	
Attorney Docket Number	108328.00146 (AVSI-0023)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/	34	KOTZMANN, H., Yilmaz, N., Lercher, P., Riedl, M., Schmidt, A., Schuster, E., Kreuzer, S., Geyer, G., Frisch, H., Horl, W. H., Mayer, G., and Luger, A. (2001). Differential effects of growth hormone therapy in malnourished hemodialysis patients. <i>Kidney Int.</i> 60, 1578-1585.	
/	35	LAL, S. O., Wolf, S. E., and Herndon, D. N. (2000). Growth hormone, burns and tissue healing. <i>Growth Horm. IGF. Res.</i> 10 Suppl B:S39-43., S39-S43.	
/	36	LEROITH, D., Yanowski, J., Kaldjian, E. P., Jaffe, E. S., LeRoith, T., Purdue, K., Cooper, B. D., Pyle, R., and Adler, W. (1996). The effects of growth hormone and insulin-like growth factor I on the immune system of aged female monkeys. <i>Endocrinology</i> 137, 1071-1079.	
/	37	LESBORDES, J. C., Bordet, T., Haase, G., Castelnau-Ptakhine, L., Rouhani, S., Gilgenkrantz, H., and Kahn, A. (2002). In vivo electrotransfer of the cardiotrophin-1 gene into skeletal muscle slows down progression of motor neuron degeneration in pmn mice. <i>Hum. Mol. Genet.</i> 11, 1615-1625.	
/	38	MANDERS, P. and Thomas, R. (2000). Immunology of DNA vaccines: CpG motifs and antigen presentation. <i>Inflamm. Res.</i> 49, 199-205.	
/	39	MAYO, K. E., Cerelli, G. M., Rosenfeld, M. G., and Evans, R. M. (1985). Characterization of cDNA and genomic clones encoding the precursor to rat hypothalamic growth hormone-releasing factor. <i>Nature</i> 314, 464-467.	
/	40	MCCLUSKIE, M. J., Weeratna, R. D., and Davis, H. L. (2000). The role of CpG in DNA vaccines. <i>Springer Semin. Immunopathol.</i> 22, 125-132.	
/	41	MCRORY, J. E., Parker, R. L., and Sherwood, N. M. (1997). Expression and alternative processing of a chicken gene encoding both growth hormone-releasing hormone and pituitary adenylate cyclase-activating polypeptide. <i>DNA Cell Biol.</i> 16, 95-102.	
/	42	MELMED, S. (1991). Extrapituitary Acromegaly. [Review]. <i>Endocrinology & Metabolism Clinics of North America</i> 20, 507-518.	
/	43	MULLIGAN, K., Tai, V. W., and Schambelan, M. (1999). Use of growth hormone and other anabolic agents in AIDS wasting. <i>JPEN J. Parenter. Enteral Nutr.</i> 23, S202-S209.	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/619,939
		Filing Date	7/15/2003
		First Named Inventor	Draghia-Akli, Ruxandra
		Group Art Unit	
		Examiner Name	
Sheet 6 of 6 Sheets	Attorney Docket Number	108328.00146 (AVSI-0023)	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/	44	NARUM, D. L., Kumar, S., Rogers, W. O., Fuhrmann, S. R., Liang, H., Oakley, M., Taye, A., Sim, B. K., and Hoffman, S. L. (2001). Codon optimization of gene fragments encoding Plasmodium falciparum merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. Infect. Immun. 69, 7250-7253.	
/	45	SCHEULE, R. K. (2000). The role of CpG motifs in immunostimulation and gene therapy. Adv. Drug Deliv. Rev. 44, 119-134.	
/	46	SHI, H., Yan, P. S., Chen, C. M., Rahmatpanah, F., Lofton-Day, C., Caldwell, C. W., and Huang, T. H. (2002). Expressed CpG island sequence tag microarray for dual screening of DNA hypermethylation and gene silencing in cancer cells. Cancer Res. 62, 3214-3220.	
/	47	SHIRAISHI, M., Sekiguchi, A., Terry, M. J., Oates, A. J., Miyamoto, Y., Chuu, Y. H., Munakata, M., and Sekiya, T. (2002). A comprehensive catalog of CpG islands methylated in human lung adenocarcinomas for the identification of tumor suppressor genes. Oncogene 21, 3804-3813.	
/	48	SOUBRIER, F., Cameron, B., Manse, B., Somarriba, S., Dubertret, C., Jaslin, G., Jung, G., Caer, C. L., Dang, D., Mouvault, J. M., Scherman, D., Mayaux, J. F., and Crouzet, J. (1999). pCOR: a new design of plasmid vectors for nonviral gene therapy. Gene Ther. 6, 1482-1488.	
/	49	WOLFF, J. A., Ludtke, J. J., Acsadi, G., Williams, P., and Jani, A. (1992). Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Human Molecular Genetics 1, 363-369.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.